Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer
Acta Biomaterialia · 2023-09 · 168 · 529-539
DOI: 10.1016/j.actbio.2023.07.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2023-09. Verfasst von Ri Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and …. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pancreatic cancer (PC) stands as a most deadly malignancy due to few effective treatments in the clinics. KRAS G12D mutation is a major driver for most PC cases, and silencing of KRAS G12D is considered as a potential therapeutic strategy for PC, which is nevertheless crippled by lacking a pragmatic delivery system for siRNA against KRAS G12D (siKRAS). Here, we report that cRGD peptide-modified bioresponsive chimaeric polymersomes (cRGD-BCP) mediate highly efficient siKRAS delivery to PANC-1 tumor, potently silencing KRAS G12D mRNA in tumor cells and effectively suppressing PC tumor growth in mice. cRGD-BCP exhibited remarkable encapsulation of siKRAS (loading content > 14 wt.%, loading efficiency > 90%) to form stable and uniform (ca. 68 nm) nanovesicles (cRGD-BCP-siKRAS). Of note, cRGD density greatly impacted the cellular uptake and silencing efficiency of cRGD-BCP-siKRAS in PANC-1 cells, in which an optimal cRGD density of 15.7 mol.% achieved 3.7- and 3.6-fold enhancement of internalization and gene silencing, respectively, compared with non-targeted BCP-siKRAS. cRGD-BCP-siKRAS was practically intact after 3-week storage at 4°C. Intriguingly, cRGD-BCP-siKRAS markedly enhanced the uptake of siKRAS in PANC-1 tumor, and at a siKRAS dose of 3 mg/kg knocked down 90% KRAS G12D gene, resulting in potent tumor inhibition and extraordinary survival benefits (median survival time: 101 days versus 38 (PBS group) and 59 days (BCP-siKRAS)) with 40% mice achieved complete regression. It appears that cRGD-mediated nanodelivery of siKRAS provides a potential cure for pancreatic cancer. STATEMENT OF SIGNIFICANCE: Small interfering RNA (siRNA) emerges as a specific and powerful biopharmaceuticals against cancers; however, inefficient in vivo delivery impedes its clinical translation. In spite of the fact that KRAS G12D mutation has been identified as a major driver for most pancreatic cancer, its notorious non-druggability renders little success on development of molecular targeted drugs. Pancreatic cancer is deemed as current king-of-cancer. Here, we show that cyclic RGD peptide installed bioresponsive polymersomes are able to efficiently deliver siRNA against KRAS G12D to pancreatic tumor, resulting in 90% gene knock-down and effective tumor inhibition. Strikingly, two out of five mice have been cured. This targeted nanodelivery of siRNA provides a high-efficacy treatment strategy for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China; College of Ph…
- Suzhou GenePharma Co., Ltd., Suzhou 215123, PR China.
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China. Electronic ad…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, R., Du, H., Cheng, L., Zhang, P., Meng, F., & Zhong, Z. (2023). Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer. Acta Biomaterialia, 168, 529-539. https://doi.org/10.1016/j.actbio.2023.07.008
Vancouver
Huang R, Du H, Cheng L, Zhang P, Meng F, Zhong Z. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer. Acta Biomaterialia. 2023;168:529-539. doi:10.1016/j.actbio.2023.07.008
BibTeX
@article{Huang2023,
author = {Huang, Ri and Du, Hong and Cheng, Liang and Zhang, Peizhuo and Meng, Fenghua and Zhong, Zhiyuan},
title = {Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer},
journal = {Acta Biomaterialia},
year = {2023},
volume = {168},
pages = {529--539},
doi = {10.1016/j.actbio.2023.07.008}
}
EUVIMED